此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors

2026年5月6日 更新者:Corregene Biotechnology Co., Ltd

A Phase I First-In-Human Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of CRPA1A2, a Bispecific T Cell Engager, in Patients With HLA-A*02:01 and MAGE-A1 Positive Advanced Solid Tumors

This is a Phase I, first-in-human, open-label study of CRPA1A2, a bispecific T-cell engager, in participants with HLA-A*02:01-positive and MAGE-A1-positive advanced solid tumors. The study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of CRPA1A2, and to identify recommended dose(s) for further evaluation.

The study consists of 2 parts: a dose escalation part (Part A) and a dose optimization part (Part B). In Part A, participants will receive escalating doses of CRPA1A2 to determine the recommended dose(s) for optimization, with additional backfill cohorts permitted. In Part B, 2 to 3 selected recommended dose(s) will be further evaluated in participants with selected tumor types to better characterize safety and preliminary anti-tumor activity.

CRPA1A2 will be administered by intravenous infusion in 28-day cycles, starting at 0.0003 mg/kg. Weekly dosing is planned, although alternative dosing schedules may be explored based on emerging data. Treatment will continue until disease progression, intolerable toxicity, initiation of new anti-tumor therapy, other discontinuation criteria are met, or study termination.

研究概览

研究类型

介入性

注册 (估计的)

192

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100142

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  1. Patients with a histological and/or cytological confirmed locally advanced or metastatic unresectable solid tumor (including but not limited to esophageal squamous cell carcinoma, hepatocellular carcinoma, head and neck squamous cell carcinoma and lung squamous cell carcinoma) who have experienced disease progression following available standard therapy and for whom no further standard treatment options are available.
  2. Patients with confirmed positive expression of MAGE-A1 (H-score ≥1, testing by IHC for FFPE) by central lab.
  3. Patients with positive HLA-A*02:01 (confirmed by the central lab).
  4. There must be at least one measurable lesion per RECIST v1.1 criteria. (Lesions that have received radiotherapy previously cannot be considered target lesions unless there is evident progression after radiotherapy).
  5. Eastern Cooperative Oncology Group (ECOG) performance status: 0-1.
  6. Life expectancy ≥ 3 months, in the opinion of the investigator.
  7. Has adequate organ function, as demonstrated by laboratory values obtained during the screening period.
  8. Participants (both males and females) of childbearing potential must agree to use highly efficient contraception from the time of signing the informed consent form until 6 months after the last dose of the investigational drug.

Exclusion Criteria:

  1. Patients with history of other malignancies (within 2 years prior to signing the ICF) are excluded, except for those with cured stage IB or earlier stage cervical cancer, non-invasive basal cell or squamous cell skin cancer, malignant melanoma in complete remission (CR) for over 10 years, or other malignancies in complete remission (CR) for over 5 years.
  2. Patients with positive HLA-A*02:05 (confirmed by the central lab).
  3. Patients with known sensitivity or immediate hypersensitivity to any components of CRPA1A2 or ingredients of CRPA1A2 injection.
  4. Patients who have been exposed to other MAGE-A1 targeted therapy.
  5. With clinically significant cardiovascular diseases, including but not limited to:

    1. History of heart failure, myocardial ischemia or infarction, unstable angina, arrhythmias, or New York Heart Association (NYHA) Class III-IV within the past 6 months or currently.
    2. With prolonged QT/QTc intervals on the electrocardiogram during the screening period (QTcF: > 480 ms).
    3. Echocardiogram (ECHO) indicates a left ventricular ejection fraction (LVEF) of ≤50% at screening.
    4. Poorly controlled hypertension at screening (systolic blood pressure ≥150 mmHg, diastolic blood pressure ≥100 mmHg) despite pharmacological treatment.
    5. History of vascular angioplasty, coronary artery bypass grafting, or other cardiac surgical procedures.
  6. With clinically significant active hepatitis B, HBsAg or HBcAb positive and have an HBV-DNA level above the detection limit at screening (i.e., the upper limit of normal values at each research center's laboratory). With the exception for those that have achieved HBV-DNA negativity after antiviral treatment and have received at least 2 weeks of antiviral therapy before the initial dosing. Additionally, they must be willing to continue antiviral therapy for hepatitis B throughout the study period. For patients with hepatocellular carcinoma, HBV DNA must be <1000 IU/mL for study eligibility.
  7. Clinically significant active hepatitis C, indicated by positive HCV antibodies and HCV-RNA levels higher than the detection limit at screening (upper limit of normal values).
  8. Positive Treponema pallidum antibodies (TP-Ab) and positive result for nonspecific syphilis antibodies titer (RPR) at screening.
  9. Prior or concurrent therapies/procedures that may confound study evaluation or increase risk, including recent participation in another clinical study; recent anticancer therapy, investigational treatment, or invasive investigational medical device use; major surgery without full recovery; prior solid organ transplantation or allogeneic hematopoietic stem cell transplantation; recent autologous hematopoietic stem cell transplantation; or planned transplantation during the study period.
  10. Active, uncontrolled, or clinically significant medical conditions that may increase the risk of study participation or interfere with study assessments, including severe infection; symptomatic or uncontrolled central nervous system or leptomeningeal metastases; clinically significant pulmonary disease (e.g., interstitial lung disease/pneumonitis); coagulation or bleeding disorders; autoimmune disease or immunodeficiency (including HIV infection); or significant neurologic or psychiatric disorders.
  11. Unresolved toxicities or other conditions considered by the investigator to make the participant unsuitable for the study, including failure to recover adequately from prior anticancer treatment-related toxicities, prior Grade ≥2 ICANS after T-cell engager or CAR-T therapy, clinically significant abnormal laboratory findings, or other severe/uncontrolled acute or chronic diseases, alcohol abuse, or substance misuse.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Part A Dose Escalation
Participants will receive CRPA1A2 by intravenous infusion in 28-day cycles in the dose-escalation part of the study. Treatment will start at 0.0003 mg/kg and proceed through protocol-defined escalating dose levels using a standard dosing approach and/or a step-up dosing strategy, as applicable. This arm is designed to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity and to support identification of the recommended dose(s) for optimization (RDO[s]).
CRPA1A2 is an investigational bispecific T-cell engager administered by intravenous infusion in 28-day cycles. In Part A, treatment will start at 0.0003 mg/kg and proceed according to protocol-defined escalating dose levels. Weekly dosing is planned, although alternative dosing schedules may be explored during Part A based on emerging PK/PD, safety, tolerability, and efficacy data. A standard dosing approach and/or a step-up dosing strategy may be used. In Part B, participants will receive protocol-defined selected recommended dose(s) for optimization. Treatment will continue until disease progression, intolerable toxicity, initiation of new anti-tumor therapy, fulfillment of other protocol-defined discontinuation criteria, or study termination, whichever occurs first.
实验性的:Part B RDO 1
Participants with selected tumor types will be randomized in Part B to receive CRPA1A2 at Recommended Dose for Optimization 1 (RDO 1), administered by intravenous infusion in 28-day cycles according to the protocol-defined regimen, to further characterize safety and preliminary anti-tumor activity.
CRPA1A2 is an investigational bispecific T-cell engager administered by intravenous infusion in 28-day cycles. In Part A, treatment will start at 0.0003 mg/kg and proceed according to protocol-defined escalating dose levels. Weekly dosing is planned, although alternative dosing schedules may be explored during Part A based on emerging PK/PD, safety, tolerability, and efficacy data. A standard dosing approach and/or a step-up dosing strategy may be used. In Part B, participants will receive protocol-defined selected recommended dose(s) for optimization. Treatment will continue until disease progression, intolerable toxicity, initiation of new anti-tumor therapy, fulfillment of other protocol-defined discontinuation criteria, or study termination, whichever occurs first.
实验性的:Part B RDO 2
Participants with selected tumor types will be randomized in Part B to receive CRPA1A2 at Recommended Dose for Optimization 2 (RDO 2), administered by intravenous infusion in 28-day cycles according to the protocol-defined regimen, to further characterize safety and preliminary anti-tumor activity.
CRPA1A2 is an investigational bispecific T-cell engager administered by intravenous infusion in 28-day cycles. In Part A, treatment will start at 0.0003 mg/kg and proceed according to protocol-defined escalating dose levels. Weekly dosing is planned, although alternative dosing schedules may be explored during Part A based on emerging PK/PD, safety, tolerability, and efficacy data. A standard dosing approach and/or a step-up dosing strategy may be used. In Part B, participants will receive protocol-defined selected recommended dose(s) for optimization. Treatment will continue until disease progression, intolerable toxicity, initiation of new anti-tumor therapy, fulfillment of other protocol-defined discontinuation criteria, or study termination, whichever occurs first.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of dose-limiting toxicities (DLTs) in Part A
大体时间:Day 28
Frequency and type of dose-limiting toxicities (DLTs) during the protocol-defined DLT evaluation period in the dose-escalation phase (Part A).
Day 28
Incidence of treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), and clinically significant changes in safety tests
大体时间:up tp 30 months
Frequency and type of treatment-emergent adverse events, treatment-related adverse events, and clinically significant changes in protocol-specified safety tests in Parts A and B.
up tp 30 months
Maximum tolerated dose (MTD) and/or recommended dose(s) for optimization (RDO[s]) and dosing schedule in Part A
大体时间:Day 1, Day 8, Day 15, Day 28
Identification of the maximum tolerated dose and/or recommended dose(s) for optimization and dosing schedule of CRPA1A2 based on an integrated assessment of safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in the dose-escalation phase (Part A).
Day 1, Day 8, Day 15, Day 28
Objective response rate (ORR) per RECIST v1.1 in Part B
大体时间:up to 30 months
Proportion of participants with a best overall response of complete response or partial response according to RECIST v1.1 in the dose-optimization phase (Part B).
up to 30 months
Duration of response (DoR) per RECIST v1.1 in Part B
大体时间:up to 30 months
Time from the first documented objective response to the first documented disease progression or death, whichever occurs first, according to RECIST v1.1 in the dose-optimization phase (Part B).
up to 30 months

次要结果测量

结果测量
措施说明
大体时间
Peak Plasma concentration (Cmax) of CRPA1A2
大体时间:Day 1, Day 3, Day 5, Day 8,Day15, Day 22
Peak Plasma concentration (Cmax) of CRPA1A2 in Parts A and B.
Day 1, Day 3, Day 5, Day 8,Day15, Day 22
Area under the plasma concentration versus time curve (AUC) of CRPA1A2
大体时间:Day 1, Day 3, Day 5, Day 8, Day 15, Day 22
Area under the plasma concentration versus time curve (AUC) of CRPA1A2 in Part A and Part B
Day 1, Day 3, Day 5, Day 8, Day 15, Day 22
Disease control rate (DCR) and progression-free survival (PFS) per RECIST v1.1 in Part A and Part B.
大体时间:up tp 30 months
Preliminary anti-tumor activity of CRPA1A2 assessed by DCR and PFS according to RECIST v1.1.
up tp 30 months
Objective response rate (ORR) and duration of response (DoR) per RECIST v1.1 in Part A.
大体时间:up to 30 months
Preliminary anti-tumor activity of CRPA1A2 assessed by ORR and DoR according to RECIST v1.1 in the dose-escalation phase (Part A).
up to 30 months
Objective response rate (ORR), duration of response (DoR), disease control rate (DCR), and progression-free survival (PFS) per iRECIST
大体时间:up to 30 months
Preliminary anti-tumor activity of CRPA1A2 assessed by ORR, DoR, DCR, and PFS according to iRECIST.
up to 30 months
Overall survival (OS)
大体时间:up to 30 months
Time from first dose to death from any cause in Parts A and B.
up to 30 months

其他结果措施

结果测量
措施说明
大体时间
Immunogenicity
大体时间:up to 30 months
Incidence of detectable anti-CRPA1A2 antibodies
up to 30 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年5月29日

初级完成 (估计的)

2030年3月30日

研究完成 (估计的)

2030年9月30日

研究注册日期

首次提交

2026年4月22日

首先提交符合 QC 标准的

2026年5月6日

首次发布 (实际的)

2026年5月13日

研究记录更新

最后更新发布 (实际的)

2026年5月13日

上次提交的符合 QC 标准的更新

2026年5月6日

最后验证

2026年4月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

No individual participant data are planned to be shared at this time.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅